These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32876799)

  • 21. Preclinical challenges for developing long acting intravitreal medicines.
    Awwad S; Henein C; Ibeanu N; Khaw PT; Brocchini S
    Eur J Pharm Biopharm; 2020 Aug; 153():130-149. PubMed ID: 32445965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents.
    Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M
    AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
    Chang HY; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments.
    Li Z; Yu X; Li Y; Verma A; Chang HP; Shah DK
    AAPS J; 2021 May; 23(3):62. PubMed ID: 33942169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans.
    Jagdale P; Sepp A; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):607-624. PubMed ID: 36266517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical validation of translational antibody PBPK model using tissue distribution data generated with
    Liu S; Li Z; Huisman M; Shah DK
    J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):377-394. PubMed ID: 37382712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
    Hu S; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
    Abuqayyas L; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody Format and Serum Disposition Govern Ocular Pharmacokinetics of Intravenously Administered Protein Therapeutics.
    Shivva V; Boswell CA; Rafidi H; Kelley RF; Kamath AV; Crowell SR
    Front Pharmacol; 2021; 12():601569. PubMed ID: 34025395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
    Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
    Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models.
    Fronton L; Pilari S; Huisinga W
    J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):87-107. PubMed ID: 24493102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
    Khot A; Tibbitts J; Rock D; Shah DK
    AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
    Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab.
    Franz M; Jairam RK; Kuepfer L; Hanke N
    Front Pharmacol; 2024; 15():1418870. PubMed ID: 39411068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies.
    Liu S; Shah DK
    AAPS J; 2023 Apr; 25(3):48. PubMed ID: 37118220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
    Garg A; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs.
    Huang HW; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2024 Dec; 51(6):621-638. PubMed ID: 37947924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration.
    Bussing D; Li Z; Li Y; Chang HP; Chang HY; Guo L; Verma A; Shah DK
    AAPS J; 2021 Nov; 23(6):116. PubMed ID: 34750690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan.
    Shah DK; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):55-69. PubMed ID: 24368689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody.
    Heiskanen T; Heiskanen T; Kairemo K
    Curr Pharm Des; 2009; 15(9):988-1007. PubMed ID: 19275663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.